Skip to content
Application 203756
- Type
- NDA
- Sponsor
- EXELIXIS
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | COMETRIQ | CABOZANTINIB S-MALATE | CAPSULE;ORAL | EQ 20MG BASE | Yes | Yes |
| 002 | COMETRIQ | CABOZANTINIB S-MALATE | CAPSULE;ORAL | EQ 80MG BASE | Yes | No |
NDC Listings For This Application#
NDC, Name, Nonproprietary name table| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|
| 42388-011 | COMETRIQ | cabozantinib | Exelixis, Inc. | NDA | Current |
| 42388-011 | COMETRIQ | cabozantinib | Exelixis, Inc. | NDA | Current |
| 42388-011 | COMETRIQ | cabozantinib | Exelixis, Inc. | NDA | Current |
| 42388-011 | COMETRIQ | cabozantinib | Exelixis, Inc. | NDA | Current |
| 42388-012 | COMETRIQ | cabozantinib | Exelixis, Inc. | NDA | Current |
| 42388-012 | COMETRIQ | cabozantinib | Exelixis, Inc. | NDA | Current |
| 42388-012 | COMETRIQ | cabozantinib | Exelixis, Inc. | NDA | Current |
| 42388-012 | COMETRIQ | cabozantinib | Exelixis, Inc. | NDA | Current |
| 42388-013 | COMETRIQ | cabozantinib | Exelixis, Inc. | NDA | Current |
| 42388-013 | COMETRIQ | cabozantinib | Exelixis, Inc. | NDA | Current |
| 42388-013 | COMETRIQ | cabozantinib | Exelixis, Inc. | NDA | Current |
| 42388-013 | COMETRIQ | cabozantinib | Exelixis, Inc. | NDA | Current |